Drug Information

Drug General Information
Drug ID
D0PZ1E
Former ID
DNCL002554
Drug Name
TRC 105
Indication Fallopian tube cancer; Peritoneal cancer; Macular degeneration; Ovarian cancer [ICD9: 140-229, 183.2, 221.0, 362.5, 183; ICD10:C57, D28, H35.3, C56] Phase 2 [524123]
Company
TRACON Pharmaceuticals
Target and Pathway
Target(s) Endoglin Target Info Modulator [532978]
References
Ref 524123ClinicalTrials.gov (NCT01727089) Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer. U.S. National Institutes of Health.
Ref 532978An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer. Clin Cancer Res. 2014 Dec 1;20(23):5918-26.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.